ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California. Show more

Location: 3530 John Hopkins Court, San Diego, CA, 92121, United States | Website: https://immunitybio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.24B

52 Wk Range

$1.83 - $7.48

Previous Close

$2.37

Open

$2.38

Volume

6,307,524

Day Range

$2.29 - $2.40

Enterprise Value

2.622B

Cash

153.7M

Avg Qtr Burn

-87.39M

Insider Ownership

69.20%

Institutional Own.

13.24%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Anktiva (N-803) + BCG Details
Non-muscle invasive bladder cancer

Approved

Update

Phase 2/3

Data readout

PD-L1 t-haNK Details
Pancreatic cancer

Phase 2/3

Update

Phase 2

Data readout

Phase 2

Data readout

ANKTIVA Details
Lymphopenia

Phase 2

Update

Phase 1/2

Initiation

CAR-NK / CD19 t-haNK Details
Non-Hodgkin lymphoma

Phase 1

Update

hAd5-COVID-19 Details
Vaccine, COVID-19

Failed

Discontinued

N-803 (Anktiva), haNK and Avelumab Details
Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer

Failed

Discontinued